Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy

Blood Reviews

Volumn 29, Issue 1, 2015, Pages 25-32

  Bryan, Locke J ^a   Gordon, Leo I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Follicular lymphoma; Hematologic malignancies; Hodgkin lymphoma; Monoclonal antibody; Non Hodgkin lymphoma (NHL); Plasma cell myeloma (PCM); Programmed Death 1 (PD 1)

Indexed keywords

AMP 224; AMP 514; CYCLOPHOSPHAMIDE; DASATINIB; DENDRITIC CELL VACCINE; DEXAMETHASONE; DURVALUMAB; IPILIMUMAB; LENALIDOMIDE; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COUGHING; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DISEASE SPECIFIC SURVIVAL; DRUG DOSE ESCALATION; FATIGUE; FOLLICULAR LYMPHOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; INFUSION RELATED REACTION; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOCYTOMA; MAXIMUM TOLERATED DOSE; MELANOMA; MINIMAL RESIDUAL DISEASE; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; T CELL LYMPHOMA; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR ESCAPE;

EID: 84921793999     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.09.004     Document Type: Article

References (56)

1. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37.
2. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
3. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
4. Slavin S., Morecki S., Weiss L., Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 2002, 11:265-276.
5. Gricks C.S., Gribben J.G. Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity. Curr Pharm Des 2003, 9:1889-1903.
6. Rivoltini L., Canese P., Huber V., Iero M., Pilla L., Valenti R., et al. Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?. Expert Opin Biol Ther 2005, 5:463-476.
7. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006, 16:3-15.
8. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
9. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992, 11:3887-3895.
10. Blank C., Kuball J., Voelkl S., Wiendl H., Becker B., Walter B., et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006, 119:317-327.
11. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
12. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005, 25:9543-9553.
13. Seo S.K., Seo H.M., Jeong H.Y., Choi I.W., Park Y.M., Yagita H., et al. Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol Lett 2006, 102:222-228.
14. Quezada S.A., Peggs K.S. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer 2013, 108:1560-1565.
15. Okazaki T., Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006, 27:195-201.
16. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007, 81:4215-4225.
17. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
18. Urbani S., Amadei B., Tola D., Pedrazzi G., Sacchelli L., Cavallo M.C., et al. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol 2008, 48:548-558.
19. Norris S., Coleman A., Kuri-Cervantes L., Bower M., Nelson M., Goodier M.R. PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. Viral Immunol 2012, 25:329-332.
20. Das S., Suarez G., Beswick E.J., Sierra J.C., Graham D.Y., Reyes V.E. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J Immunol 2006, 176:3000-3009.
21. Lepenies B., Jacobs T. The role of negative costimulators during parasitic infections. Endocr Metab Immune Disord Drug Targets 2008, 8:279-288.
22. Jacobsen E.D. Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma. J Clin Oncol 2013, 31:4268-4270.
23. Chen B.J., Chapuy B., Ouyang J., Sun H.H., Roemer M.G., Xu M.L., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013, 19:3462-3473.
24. Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116:3268-3277.
25. Taube J.M., Anders R.A., Young G.D., Xu H., Sharma R., McMiller T.L., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012, 4:127ra37.
26. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-1096.
27. Liu J., Hamrouni A., Wolowiec D., Coiteux V., Kuliczkowski K., Hetuin D., et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110:296-304.
28. Dorfman D.M., Brown J.A., Shahsafaei A., Freeman G.J. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006, 30:802-810.
29. Chemnitz J.M., Eggle D., Driesen J., Classen S., Riley J.L., Debey-Pascher S., et al. RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. Blood 2007, 110:3226-3233.
30. Shimauchi T., Kabashima K., Nakashima D., Sugita K., Yamada Y., Hino R., et al. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma. Int J Cancer 2007, 121:2585-2590.
31. Tamura H., Dan K., Tamada K., Nakamura K., Shioi Y., Hyodo H., et al. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 2005, 11:5708-5717.
32. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R.D., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851-862.
33. Carreras J., Lopez-Guillermo A., Roncador G., Villamor N., Colomo L., Martinez A., et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009, 27:1470-1476.
34. Tzankov A., Meier C., Hirschmann P., Went P., Pileri S.A., Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008, 93:193-200.
35. Xerri L., Chetaille B., Serriari N., Attias C., Guillaume Y., Arnoulet C., et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008, 39:1050-1058.
36. Muenst S., Hoeller S., Dirnhofer S., Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009, 40:1715-1722.
37. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007, 19:813-824.
38. Muenst S., Hoeller S., Willi N., Dirnhofera S., Tzankov A. Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers 2010, 29:47-53.
39. Yang Z.-Z., Grote D., Ziesmer S., Ansell S. PD-1 expression defines Two distinct T-cell subpopulations that differentially impact patient outcomes in follicular lymphoma. ASH 55th Annual Meeting 2013, [New Orleans, LA].
40. Fest T., Rosille D., Gressier M., Maucort-Boulch D., Darnotte D., Pangault C., et al. Blood soluble PD-L1 protein in aggressive diffuse large B-cell lymphoma impacts patient's overall survival. 55th ASH Annual Meeting 2013, Blood, 122 (21) [New Orleans, LA].
41. Intlekofer A.M., Thompson C.B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013, 94:25-39.
42. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
43. Armand P., Nagler A., Weller E.A., Devine S.M., Avigan D.E., Chen Y.B., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013, 31:4199-4206.
44. Westin J.R., Chu F., Zhang M., Fayad L.E., Kwak L.W., Fowler N., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014, 15:69-77.
45. Hardy B., Yampolski I., Kovjazin R., Galli M., Novogrodsky A. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice. Cancer Res 1994, 54:5793-5796.
46. Raiter A., Novogrodsky A., Hardy B. Activation of lymphocytes by BAT and anti CTLA-4: comparison of binding to T and B cells. Immunol Lett 1999, 69:247-251.
47. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
48. Armand P., Welch S., Kim H.T., LaCasce A.S., Jacobsen E.D., Davids M.S., et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol 2013, 160:608-617.
49. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
50. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.
51. Selby M., Engelhardt J., Lu L., Quigley M., Wang C., Bingliang C., et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J Clin Oncol 2013.
52. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
53. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32:1020-1030.
54. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24:207-212.
55. Infante J., Powderly J.D., Burris H., Kittaneh M., Grice J., Smothers J., et al. Clinical and pharmacodynamics (PD) results of a Phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. ASCO Annual Meeting 2013 2013, JCO, [Chicago].
56. Mkrtichyan M., Najjar Y.G., Raulfs E.C., Liu L., Langerman S., Guittard G., et al. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J Immunol 2012, 189:2338-2347.